Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study
نویسندگان
چکیده
منابع مشابه
Cladribine tablets for the treatment of relapsing-remitting multiple sclerosis.
INTRODUCTION Multiple sclerosis (MS) is a chronic immune-mediated disorder of the central nervous system leading to progressive neurodegeneration and disability. Until 2010, all approved disease-modifying drugs for MS required parenteral administration, which is associated with suboptimal adherence. It was anticipated that new approaches to treatment, including oral agents such as cladribine ta...
متن کاملCladribine in the treatment of multiple sclerosis
ISSN 2041-6792 10.4155/CLI.10.32 © 2011 Future Science Ltd Treatment with cladribine leads to a preferential and sustained reduction in lymphocytes and monocytes, resulting in long-lasting depletion of CD4+ and CD8+ T cells. In the Phase III placebo-controlled trial in relapsing–remitting multiple sclerosis (the CLARITY study), oral cladribine at 96 weeks significantly reduced annual relapse ra...
متن کاملCladribine in aggressive forms of multiple sclerosis.
Cladribine (2-chlorodeoxyadenosine) is an immunosuppressant drug previously evaluated in multiple sclerosis (MS) with variable results. We report six patients with aggressive relapsing MS who despite a poor response to other therapies had a favourable clinical evolution after cladribine. Four women and two men with a rapid increase in the number and severity of relapses leading to increasing di...
متن کاملEmerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets
Multiple sclerosis (MS) is a chronic inflammatory disorder of the central nervous system (CNS) that represents one of the first causes of neurological disability in young adults. Although the pathogenesis of MS is still unclear, an autoimmune mechanism has been demonstrated. According to this evidence in the last 15 years different treatments acting on the immune system have been developed. Cur...
متن کاملSafety and tolerability of subcutaneous cladribine therapy in progressive multiple sclerosis.
OBJECTIVE To evaluate the safety and tolerability of subcutaneous (s.c.) cladribine therapy in patients with chronic progressive multiple sclerosis (CPMS), and to evaluate the effects on lymphocyte subsets. BACKGROUND Cladribine, a synthetic antineoplastic agent with immunosuppressive effects, may favourably affect the course of CPMS. However results of a previous reported clinical trial show...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Multiple Sclerosis Journal
سال: 2011
ISSN: 1352-4585,1477-0970
DOI: 10.1177/1352458510391344